Glenmark Pharma USA bags ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules

29 Jul 2022 , 01:26 PM

Glenmark Pharmaceuticals Limited informed that USA arm Glenmark Pharmaceuticals Inc., has received final USFDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, the generic version of Allergan Pharmaceuticals International Limited’s Taytulla 1 Capsules.

Taytulla Capsules market 2 achieved annual sales of approximately $85.9 million, according to IQVIATM sales data for the 12-month period ending May 2022.

Glenmark’s current portfolio includes 177 products that are authorized for distribution in the United States, as well as 47 ANDAs that are awaiting FDA approval.

In addition to these internal filings, Glenmark continues to identify and explore external development opportunities to supplement and accelerate the growth of its existing pipeline and portfolio.

Annual Sales value is as per IQVIATM National Sales Perspectives: Retail & Non-Retail, May 2022.

At around 1.32 PM, Glenmark Pharma was trading at Rs377.85 down by Rs2.05 or 0.54% from its previous closing of Rs379.90 on the BSE. The scrip hit intraday high and low of Rs383 and Rs375.20 respectively.

For any queries related to the article, please contact: [e-mail]